chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Severe chills, nausea, headache, muscle ache in arm, very sleepy - lasted 14 hours then just had a headache and sleepy. Took Tylenol next day. Day 2 - still sleepy and sore arm. Day 3 sore muscle in arm where vaccination took place.
Received vaccination 10/30/07; returned to doctor with pain in left shoulder (same as vaccinated arm) within two months; began experiencing pain, numbness, cognitive changes 5 months later w/no previous history; admitted to hospital after symptoms worsened; diagnosed with Multiple Sclerosis in 04/2008; no history of any autoimmune disorders in family.  5/14/09 Hospital records received DOS 4/3/08 to 4/4/08. FINAL DIAGNOSIS: C2-C3 demyelinating lesion, single white matter lesion in the subcortical U fibers of the left frontal lobe Post vaccination ascending numbness feet, torso, hands.  ICD-9 Codes: 341.9 Demyelinating diseases of central nervous system unspecified. 3488.8 Condition of brain. 477.9 Allergic rhinitis cause unspecified.  Follow-up received on May 10, 2010 - Pt did not recover from the adverse events that were reported for this vaccination. Multiple sclerosis - Permanently disabled.
Right arm swelling below the injection site that was about 8 cm by 13 cm in size with soreness and warmth to the touch ===> Pt was directed to the ER for possible clotting of the region
Complete numbness of right middle finger and partial numbness of pointer and ring fingers. By the next day, this had progressed to the left hand with complete numbness of the left middle finger and partial numbness of the pointer and ring fingers. By the next day, experiencing extreme pain in both shoulders, elbows, wrists and hands along with the numbness in fingers on both hands.
The area is red and spreading; Stiff neck; Severe headache; This case was reported by a consumer via interactive digital media and described the occurrence of injection site erythema in a adult patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Previously administered products included Shingles vaccine (1st dose received on an unknown date).   On an unknown date, the patient received the 2nd dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced injection site erythema, stiff neck and headache. On an unknown date, the outcome of the injection site erythema, stiff neck and headache were unknown.   It was unknown if the reporter considered the injection site erythema, stiff neck and headache to be related to Shingles vaccine.  Additional detail were reported as follows: The age at vaccination was not reported. The age group was not reported but it was selected as an adult as per vaccine indication. The patient had 2nd dose of Shingles vaccine and the area was red and spreading with stiff neck and severe headache was that normal. No other information was provided. The information regarding consent to follow up was not reported
lymph node that keeps popping up; achy; chills; interesting reaction; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 57 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. Relevant medical history included: "UTI" (unspecified if ongoing); "Swollen lymph nodes" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose Number:1), for COVID-19 immunization; Shingrix vaccine; Flu shot. The following information was reported: LYMPH NODE PALPABLE (non-serious), outcome "unknown", described as "lymph node that keeps popping up"; PAIN (non-serious), outcome "unknown", described as "achy"; CHILLS (non-serious), outcome "unknown", described as "chills"; FEELING ABNORMAL (non-serious), outcome "unknown", described as "interesting reaction".  Additional information: The caller stated her first dose of the vaccine was awesome, she had not one side effect. She had the second shot on Tuesday and was already feeling under the weather when she got it with fluid in her ear but no fever. Wednesday morning she got the chills, was achy, and had all those reactions all day. The next day, yesterday, she was totally good. However, on the left side she has a lymph node that keeps popping up (she got the shot on the left side both times). This happened both times but mainly with the second. It started protruding Wednesday and it is still here, she can feel it move. The caller asked if this is normal and why she would have a swollen lymph node. After the verbal response she asked if a robust immune response was good.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
right sided weakness; prolonged hypoglycemia; developed POTS (diagnosed by clinician); This is a spontaneous report received from a contactable reporter(s) (Pharmacist).  An adult female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 3 (booster), single and (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. Relevant medical history included: "ehlers danlos" (unspecified if ongoing), notes: Ehlers danlos; "inflammatory bowel disease" (unspecified if ongoing), notes: Inflammatory bowel disease. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 1, Batch lot number unknown.), for Covid-19 immunization, reaction(s): "severe dizziness with 1st dose of vaccine". The following information was reported: ASTHENIA (non-serious), outcome "not recovered", described as "right sided weakness"; HYPOGLYCAEMIA (non-serious), outcome "not recovered", described as "prolonged hypoglycemia"; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (non-serious), outcome "not recovered", described as "developed POTS (diagnosed by clinician)". The events "right sided weakness", "prolonged hypoglycemia" and "developed pots (diagnosed by clinician)" were evaluated at the physician office visit and emergency room visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of asthenia, hypoglycaemia, postural orthostatic tachycardia syndrome.  Additional information: The patient had no Covid-19 prior vaccination. The patient has tested covid post vaccination. If the patient had any Known allergies was unknown. It was unknown if the patient had any other vaccine in four weeks.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Pt became weak, nauseous, hypotensive, tachycardic and diaphoretic about 20 min. post vaccination.
PATIENT'S COLORING TURNED PALE; PATIENT FAINTED; PATIENT BECAME RIGID AND POSTURED THEN BEGAN TO SLIDE DOWN SEAT. SECURED PATIENT FROM SLIDING TO GROUND. APPLIED COLD COMPRESS TO FOREHEAD & NECK AREA. FANNED. PATIENT RETURNED TO CONSCIOUSNESS AND STATED "I FEEL NAUSEOUS". PATIENT MOTHER STATED "I PASS OUT FREQUENTLY WHEN I EXPERIENCE PAIN. DR. TOLD ME I HAVE VASOVAGAL RESPONSE. GUESS SHE INHERITED IT FROM ME." PATIENT RESPONSIVE AND COLORING RETURNED TO CHEEKS. STATED "NOT NAUSEOUS ANY MORE. HYDRATED PATIENT WITH FRUIT JUICE. PATIENT STEADY UPON RISING AND AMBULATING. LEFT WITH MOTHER.
196 patients received 0.25mL of Moderna Covid-19 Vaccine, Bivalent; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of UNDERDOSE (196 patients received 0.25mL of Moderna Covid-19 Vaccine, Bivalent) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. On an unknown date, the patient experienced UNDERDOSE (196 patients received 0.25mL of Moderna Covid-19 Vaccine, Bivalent) and NO ADVERSE EVENT (No adverse event). At the time of the report, UNDERDOSE (196 patients received 0.25mL of Moderna Covid-19 Vaccine, Bivalent) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for UNDERDOSE (196 patients received 0.25mL of Moderna Covid-19 Vaccine, Bivalent).    Concomitant medication list was not provided.  It was reported that 196 patients received 0.25mL of Moderna COVID-19 vaccine, Bivalent.  It was unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.  Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 27-Dec-2022: Live follow up: added patient demographic details.
hair loss; This is a spontaneous report from a contactable pharmacist.  A 35-year-old nonpregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Lot number was not reported), via intramuscular, administered in arm right on 26Mar2021 09:00AM as dose 2, (at the age of 35-year-old) single for COVID-19 immunisation. The patient previously received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Lot number: EN6205), via intramuscular, administered in arm left on 05Mar2021 08:00AM as dose 1, (at the age of 35-year-old) single for COVID-19 immunisation. Medical history included hypothyroidism and known allergies: sulfa. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Concomitant medication included levothyroxine sodium (SYNTHROID). The patient received other medications within 2 weeks of vaccination. On 30Mar2021 13:00, the patient experienced significant hair loss started 3 days after second shot and is still continuing (~4 weeks post second shot). Approximately ~25percentage of hair loss from head. Not patches. Had to increase Synthroid (100 mcg to 112 mcg). No treatment was received in response to the adverse events. The patient was not diagnosed with COVID-19 prior to vaccination. Since the vaccination, patient was not tested for COVID-19. At the time of reporting, the outcome of the event was not recovered.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
The pt. received the Men B vaccine - Bexsero in the office. The pt. was sitting on the exam table and less than 1minute after receiving the vaccine the pt. passed out and fell face first onto the floor. The pt. had no warning signs or symptoms. The pt. was bleeding from a chin laceration and c/o jaw pain. EMS was called and pt was transferred to Hospital.
19 year old male given 2nd dose of vaccine then suddenly became dizzy, lightheaded, diaphoretic and momentary loss of consciousness while seated in sun at vaccine clinic. His nearby family held him and he did not fall then regained consciousness and was lowered to ground with legs elevated by medical staff. Patient was assessed with normal vital signs. 911 was called and patient was reassessed. He was not transported to the hospital. Family was encouraged to monitor symptoms and call 911 if he worsens for further evaluation.
Patient presented to hospital after a episode of unresponsiveness, upon EMS arrival they provided the patient with Narcan. LOC improved however is sats remained 30% on RA, pt was placed on NRB. Workup in hospital included EKG - prolonged QTC interval concern for TCA overdose. CXR - covid disease B/L infiltrates. Positive covid tested positive and influenza and RSV negative.  Patient completed Remdesivir per ID, doxycycline and dexamethasone
administering dose post temperature excursion outside acceptable guidelines per stability standard with no reported adverse event; Initial information received on 19-Apr-2022 regarding an unsolicited valid non-serious case received via other health professional.  This case concerns a 43 years old female patient who experienced administering dose post temperature excursion outside acceptable guidelines per stability standard with no reported adverse event while receiving vaccine DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE (Adacel).  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included: Flu   On 18-Mar-2022, the patient received a dose of suspect DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE at a dose of 0.5 ml with lot C5873AA via intramuscular route in the right deltoid for Immunization.  On 18-Mar-2022 the patient developed administering dose post temperature excursion outside acceptable guidelines per stability standard with no reported adverse event (product storage error) (same day)  following the administration of DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE. Reportedly negative 2.1 C from 07-Mar2022 until 31-Mar-2022 Did it occur due to a human error: No. Does extended stability data cover the excursion: No and in case of negative advice: was the product used by/ administered to the patient: Yes-14   Action taken: not applicable.  It was not reported if the patient received a corrective treatment for the event (administering dose post temperature excursion outside acceptable guidelines per stability standard with no reported adverse event).  At time of reporting, the outcome was Unknown for the event administering dose post temperature excursion outside acceptable guidelines per stability standard with no reported adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
I developed diarrhea and was cold and achy as if I had the flu. Several hours after the diarrhea started, I threw up. I had no energy and slept for approximately 30 hours. I never developed a fever and tested negative for COVID on June 14th. It took me until June 16th before I felt as I had before 10pm on June 12, 2022.
I have a painful nodule just below my clavicle.  My clavicle starting hurting during the afternoon on 3/12/21, and while rubbing it, I felt the nodule.  I'm hoping once my arm and armpit pain resolves, the nodule will too.
suspected vaccination failure; shingles twice; shingles twice; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, several months after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles and shingles. On an unknown date, the outcome of the vaccination failure, shingles and shingles were unknown.   It was unknown if the reporter considered the vaccination failure, shingles and shingles to be related to Shingles vaccine.  Additional details were provided as follows: The patient had reported for him/herself. The age at vaccination was not reported. Couple of months after receiving Shingles vaccine, the patient got shingles and he/she had them once again since. The patient would have them worse without it, but he/she was not convinced. This case was considered as suspected vaccination failure, since the details regarding the completion of the primary immunization and laboratory confirmation of shingles were not provided.
Patient complains of abdominal pain/discomfort, general malaise, just not feeling well since injection given.
By around 7 he was very pale and irritable.  He also wasn't that hungry.  I had him sleep with me so I could keep an eye on him.  I woke up twice between maybe ten and 230. The first time it seemed like his heart was beating very fast, but then it slowed down right away. Then I woke up cause I thought the bed was shaking, and I wondered if he was having one of those seizures, but he was still sleeping. Then he woke up between 230 and 5am. He threw up three times, mostly water.  He didn't have much of an appetite the next day, was very fussy, and seemed to have loose bowels. He's been pooping every single time he eats something. Sometimes its more like diarrhea and sometimes just regular. He's been pooping about 6 times a day since he had the vaccine.  He seems better overall now, but is still fussy (could be teething cause he was fussy before), but he is still pooping whenever he eats, even if he just pooped, hell still poop a little bit. I think the vaccine upset his bowels again. No fever at any point.
EPILEPSY, UNSPECIFIED ACUTE LACUNAR STROKE, UNSPECIFIED TYPE AND ARTERY SUPERIOR CEREBELLAR ARTERY SYNDROME
Numbness in both arms; Weakness in both arms; Tingling same arm of injection; Soreness at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (Numbness in both arms), MUSCULAR WEAKNESS (Weakness in both arms), PARAESTHESIA (Tingling same arm of injection) and VACCINATION SITE PAIN (Soreness at the injection site) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for an unknown indication.     The patient's past medical history included No adverse event (No reported medical history).    On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Jan-2021, the patient experienced HYPOAESTHESIA (Numbness in both arms), MUSCULAR WEAKNESS (Weakness in both arms), PARAESTHESIA (Tingling same arm of injection) and VACCINATION SITE PAIN (Soreness at the injection site). At the time of the report, HYPOAESTHESIA (Numbness in both arms), MUSCULAR WEAKNESS (Weakness in both arms), PARAESTHESIA (Tingling same arm of injection) and VACCINATION SITE PAIN (Soreness at the injection site) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
"I" woke up the next morning with chills; "I" woke up the next morning with chills, body aches; "I" woke up the next morning with chills, body aches, headache; "I" woke up the next morning with chills, body aches, headache, fatigue; "I" woke up the next morning with chills, bodyaches, headache, fatigue, nausea; Fever that went up to a maximum of 105.1 degrees Fahrenheit with a forehead thermometer; 10 hour after injection, "I" developed vomiting; Shoulder is very painful and stiff.; Shoulder is very painful and stiff.; This is a spontaneous report from a contactable nurse, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 06May2021 at 12:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. The medical history included renal agenesis (congenital missing kidney), history of left calf deep vein thrombosis (DVT) in 2019 and homozygous for methylenetetrahydrofolate reductase (MTHFR) c677t mutation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications included bupropion (MANUFACTURER UNKNOWN), norethindrone (ERRIN) and women's multivitamin(unspecified), all from unknown dates for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in right upper arm on 15Apr2021 (at the age of 37-years-old) as a single dose for COVID-19 immunisation.   On 06May2021, second injection was done very high up in deltoid, almost at joint and the patient's shoulder was very painful and stiff. On 06May2021 at 22:00, the patient developed vomiting. On 07May2021, the next morning the patient woke up with chills, body aches, headache, fatigue, nausea and fever that went up to a maximum of 105.1 degrees fahrenheit with a forehead thermometer. On the same day, the patient underwent body temperature test and the result was found to be 105.1 degrees fahrenheit. Therapeutic measures were taken as a result of the reported events and included treatment with ibuprofen(MANUFACTURER UNKNOWN) 800 mg on an unknown date. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, shoulder was very painful and stiff, vomiting, chills, body aches, fatigue, nausea and fever that went up to a maximum of 105.1 degrees fahrenheit were resolving at the time of this report.    No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
A few hours after being given the injection, I had a horrible headache that pounded, I have muscle soreness all over and the chills. It lasted all night long. I had to use ice packs to put on my head and my lower back.
This case was reported by a health professional and described a patient of unspecified age and gender who did not respond to immunization with hepatitis B recombinant vaccine (Engerix-B) immunization series.  The health professional stated that seven or eight patients did not respond to immunization with Engerix-B; however no patient identifiers were available. On unspecified dates, the patient received 3 doses of Engerix-B.  Subsequently, on an unspecified date later, a hepatitis B surface antibody titer indicated that the patient did not receive adequate titers.
First dose / 1.25 years ago / never received the second / dose because / the coronavirus pandemic; This case was reported by a consumer via call center representative and described the occurrence of social problem in a 73-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received first dose of Shingrix 1.25 years ago).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced social problem. On an unknown date, the outcome of the social problem was unknown.  Additional details were provided as follows: The patient reported the case for herself. The age at vaccination was not applicable to this report. The patient never received the 2nd dose of Shingrix because the patient did not leave her home due to the coronavirus pandemic and till the time of reporting, the patient had not scheduled a 2nd dose of Shingrix. The patient declined to provide any demographic or contact information due to privacy concerns and stated she had prior negative experiences with privacy concerns. No further information was reported. The reporter did not consent to follow up.